LebwohlD.: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.Eur J Cancer1998; 34: 1522–34.
3.
RixeO.: Oxaliplatin. Tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel.Biochem Pharmacol1996; 52: 1855–65.
4.
RaymondE.: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.Anticancer Drugs1997; 9: 876–85.
5.
RaymondE.: Oxaliplatin: mechanism of action and antineoplastic activity.Semin Oncol1998; Suppl. 5: 4–12.
6.
KidaniY.: Synthesis and anti-tumor activities of platinum (ii) complexes of 1,2-diaminocyclohexane isomers and their related derivatives.J Clin Hematol Oncol1977; 7: 197–209.
7.
KidaniY.: Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form.J Med Chem1978; 21: 1315–8.
8.
PendyalaL.: In vitro cytotoxicity, protein binding, red blood cell partioning and biotransformation of oxaliplatin.Cancer Res1993; 53: 5970–6.
9.
MauldinS.K.: Displacement of the bidentate malonate ligand from (d.l-trans-1,2-diaminocyclohexane) malonatoplatinum (II) by physiologically important compounds in vitro.Biochem Pharmacol1988; 37: 3321–33.
10.
Daley-YatesP.T.: Cisplatin metabolites in plasma. A study of their pharmacokinetics and importance to the nephrotoxic and antitumor activity of cisplatin.Biochem Pharmacol1984; 33: 3063–70.
11.
ScheeffE.D.: Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin.Mol Pharmacol1999; 56: 633–43.
12.
WoynarowskiJ.M.: Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.Mol Pharmacol1998; 54: 770–7.
13.
SchmidtW.: Role of carrier ligand in platinum resistance of human carcinoma cell lines.Cancer Res1993; 53: 799–805.
14.
SarisC.P.: In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.Carcinogenesis1996, 17: 2763–9.
15.
MamentaE.L.: Enhanced replicative bypass of platinum-DNA adducts in cisplatin. Resistant human ovarian carcinoma cell lines.Cancer Res1994; 54: 3500–5.
16.
NehmeA.: Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and deficient cells.Br J Cancer1999; 79: 1104–10.
17.
FinkD.: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.Cancer Res1997; 57: 1841–5.
18.
VaismanA.: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.Cancer Res1998; 58: 3579–85.
19.
ChaneyS.G.: Specificity of platinum-DNA adduct repair.J Inorg Biochem1999; 77: 71–81.
20.
ReardonJ.T.: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts.Cancer Res1999; 59: 3968–71.
21.
HessS.: Oxaliplatin: in vitro and in vivo evidence of its radiation sensitizing activity. Preclinical observations relevant to ongoing clinical trials.Proc AACR2000: abs 335.
